

# **EXHIBIT Q**

UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA

--oo--

COYNESS L. ENNIX, JR., M.D., as )  
an individual and in his )  
representative capacity under )  
Business & Professions Code )  
Section 17200 et seq., )

CERTIFIED COPY

)  
Plaintiff, )  
)  
vs. ) No. C 07-2486  
)

RUSSELL D. STANTEN, M.D., LEIGH )  
I.G. IVERSON, M.D., STEVEN A. )  
STANTEN, M.D., WILLIAM M. )  
ISENBERG, M.D., Ph.D., ALTA BATES)  
SUMMIT MEDICAL CENTER and Does 1 )  
through 100, )

)  
Defendants. )  
-----)

CONFIDENTIAL

CONFIDENTIAL

DEPOSITION OF  
LAMONT PAXTON, M.D.

-----  
December 13, 2007

REPORTER: BRANDON D. COMBS, RPR, CSR 12978

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. Yes.

2 Q. Which ones?

3 A. Summit Medical Center, San Leandro Hospital  
4 and Eden Medical Center.

5 Q. And just as a general proposition, of those  
6 three, Summit, San Leandro and Eden, which one would you  
7 say you have more peer review experience at?

8 MR. VANDALL: Objection. Vague.

9 MR. SWEET: Q. Do you understand that  
10 question?

11 A. Yes.

12 Q. So what's the answer?

13 A. I had considerable experience at Summit  
14 Medical Center as well as San Leandro Hospital.

15 Q. And to some lesser degree at Eden?

16 A. Yes.

17 Q. Okay. Can you briefly describe your vascular  
18 surgery group and how it's comprised and what your role  
19 is in that group.

20 MR. VANDALL: Can we ask one question at a  
21 time.

22 MR. SWEET: Q. Go ahead. Do you understand  
23 the question?

24 A. I do. There are four partners in practice.  
25 Shall I name them?

HANNAH KAUFMAN & ASSOCIATES, INC.

1           Q. Yeah. Go ahead.

2           A. Dr. Robert Gingery, G-i-n-g-e-r-y, is the  
3         senior partner. Dr. Arnold Levine, L-e-v-i-n-e, is the  
4         next partner. Myself, and then Dr. Michael Ingegno,  
5         I-n-g-e-g-n-o, is the fourth partner. And we're a  
6         partnership practice that -- and we practice peripheral  
7         vascular surgical procedures.

8           Q. What does that mean?

9           A. Peripheral vascular as opposed to central  
10          vascular means that we operate on the periphery of the  
11          body as opposed to the central portions, such as the  
12          brain, neurosurgeons, and the heart, cardiosurgeons.

13          Q. And so I'm clear, those things, the brain, the  
14          heart, are things you do not operate on?

15          A. That's correct.

16          Q. So is your practice comprised mostly of, I  
17          guess I would call it, either less radical vascular  
18          surgeries or more cosmetic vascular surgeries, as  
19          opposed to the more serious internal types of vascular  
20          surgeries?

21          A. No.

22          Q. What would you describe as inaccurate about my  
23          question?

24          A. The surgeries that we do are at times quite  
25          complex, much as neurosurgery and cardiac surgery, and

HANNAH KAUFMAN & ASSOCIATES, INC.

1           Q. Any other professional experience that you've  
2       had with Dr. Isenberg other than the time that you two  
3       served on the MEC together?

4           A. No.

5           Q. Do you think he had input from other people in  
6       who he should ask to be on the ad hoc committee?

7           MR. VANDALL: Calls for speculation. You can  
8       answer if you know.

9           THE WITNESS: I do not.

10          MR. SWEET: Q. Do you have any concerns about  
11       the objectivity of the surgery peer review committee at  
12       Summit?

13          MR. VANDALL: Objection. It's vague.

14          THE WITNESS: No.

15          MR. SWEET: Q. Do you have any concerns about  
16       the objectivity of the cardiothoracic surgery peer  
17       review committee at Summit?

18          MR. VANDALL: Same objection.

19          THE WITNESS: I did not serve on that  
20       committee. I don't have much of a point of view. I  
21       have no reason to question objectivity.

22          MR. SWEET: Q. Are you able to tell me how  
23       many vascular surgeons practice at Summit?

24          A. Yes.

25          Q. How many?

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. No.

2 Q. Have you ever?

3 A. I don't believe so.

4 Q. Are you a golfer?

5 A. I am.

6 Q. Okay. Steven Stanton, Dr. Steven Stanton, can  
7 you describe your social relationship with him.

8 A. Similar, we're quite good friends. We were  
9 neighbors at one time. Our ten-year-old daughters are  
10 in school together. Our wives are good friends. And  
11 unfortunately, we don't have much time to socialize  
12 together.

13 Q. I guess stating the obvious, your children,  
14 Dr. Russell Stanton's children and Dr. Steven Stanton's  
15 children all go to school together?

16 A. Yes.

17 Q. How often -- I know you said you don't have a  
18 lot of time, I certainly understand that, to socialize  
19 with Dr. Steve Stanton, but how often do you socialize  
20 with him?

21 A. I may see him outside the hospital, three or  
22 four or five times a year.

23 Q. Do you play golf with him?

24 A. No.

25 Q. Have you ever?

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. Yes.

2 Q. How many times?

3 A. Twice.

4 Q. As you sit here today, do you have a specific  
5 recollection of two times?

6 A. I believe the last time was at Spanish Bay ten  
7 years ago.

8 Q. Let me guess, you lost 15 balls. No. You're  
9 better than that. Okay.

10 A. He's the good golfer.

11 Q. What about Leigh Iverson? Do you have a  
12 social relationship with Dr. Iverson?

13 A. No.

14 Q. Dr. Isenberg, do you have a social  
15 relationship with Dr. Isenberg?

16 A. No.

17 Q. Dr. Moorstein?

18 A. No.

19 Q. Dr. Horschowitz?

20 A. No.

21 Q. We've been going an hour, I'd like to take a  
22 five-minute break. Does that work for everybody?

23 A. Of course.

24 MR. SWEET: Thank you.

25 (Recess taken.)

HANNAH KAUFMAN & ASSOCIATES, INC.

1       but I'd have to review to make certain that I was at  
2       that meeting.

3           Q. This is a document that's been previously  
4       marked as Plaintiff's 1014. Could you review this  
5       document, please.

6           MR. VANDALL: I'm sorry. I wasn't privy to  
7       the marking discussion. This is a handwritten notation  
8       that says P's 1014, which I presume was designated on  
9       the record with Ms. McClain; is that correct?

10          MR. SWEET: Sure.

11          MR. VANDALL: Okay. Thanks.

12          THE WITNESS: Okay.

13          MR. SWEET: Q. Okay. What is this document  
14       that's marked Plaintiff's 1014?

15          A. It appears to be the minutes of our surgical  
16       peer review committee meeting on April 12, 2004.

17          Q. And by looking at this document, are you able  
18       to now recall and confirm for us whether you attended  
19       this meeting?

20          A. I did attend this meeting. My name is marked  
21       as present.

22          Q. And is this the surgery peer review committee  
23       meeting where Dr. Hon Lee's opinions were discussed  
24       regarding the minimally invasive cases?

25          A. I believe that's correct.

HANNAH KAUFMAN & ASSOCIATES, INC.

1       Q. And can you tell from this document whether  
2       Dr. Hon Lee himself appeared at this meeting?

3       A. I don't see his name as being present in the  
4       names listed attending the meeting.

5       Q. So that means he was not present; correct?

6       A. I don't know the answer to that.

7       Q. Well, if he was present, he would be listed as  
8       present; right?

9                    MR. VANDALL: Objection. Document speaks for  
10          itself and the witness has provided his response.

11                  MR. SWEET: Q. Doctor?

12                  A. I don't see his name as being listed as  
13                  present, thus I would interpret that he was not present.

14                  Q. Now, was Dr. Hon Lee's opinion regarding the  
15          four minimally invasive cases conveyed to the surgery  
16          peer review committee on April 12, 2004?

17                  A. I don't know the answer to that question.

18                  Q. Does that mean you don't have a recollection  
19          of how Dr. Lee, Hon Lee's opinion was conveyed?

20                  A. Correct.

21                  Q. What was the conclusion of the surgery peer  
22          review committee regarding Dr. Lee's opinion?

23                  MR. VANDALL: Objection. It's vague as to  
24          time, are you referring to this specific meeting?

25                  MR. SWEET: Q. At this meeting.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 time -- is not about what you thought or what other  
2 people in the surgery peer review committee meeting  
3 thought.

4 My question is, to your knowledge have you  
5 ever heard of an in-field expert, Hon Lee in this case,  
6 reports to the chairman of the department of surgery  
7 that there are no quality of care concerns, yet the  
8 department of surgery brings that case to the surgery  
9 peer review committee? Have you ever heard of that  
10 happening?

11 MR. VANDALL: Object to the question, lacks  
12 foundation as to Dr. Hon Lee's being an expert,  
13 misstates the witness's prior testimony. It misstates  
14 Plaintiff's 1014, and you can answer if you can  
15 understand the question.

16 THE WITNESS: I would say that I don't have  
17 any prior experience with that.

18 MR. SWEET: Q. Still on 1022, do you still  
19 have that document?

20 A. I do.

21 Q. Did you see these minutes before the ad hoc  
22 committee met for the first time?

23 A. No.

24 Q. Were they summarized for you in any way?

25 A. No.

HANNAH KAUFMAN & ASSOCIATES, INC.

1       needed more input from experts in cardiac surgery who  
2       had no potential conflict of interest and would render a  
3       fair and impartial opinion, expert opinion in this case.

4           Q. What else? What else, why else did you send  
5       it out?

6           A. For those reasons.

7           Q. Are you suggesting that there was no  
8       cardiologist or cardiac surgeon available on the medical  
9       staff who would have objectively sat on the ad hoc  
10      committee?

11       A. No.

12       Q. There were people that could have filled that  
13      role from within; correct?

14       A. Certainly.

15       Q. Did you have discussions with Dr. Isenberg or  
16       Dr. Steven Stanton or anybody at Summit regarding the  
17       possibility of putting a cardiac surgeon or a  
18       cardiologist on the ad hoc committee?

19       A. No.

20       Q. Why was there no Kaiser surgeon on the ad hoc  
21       committee?

22           MR. VANDALL: Objection. Calls for  
23       speculation.

24           THE WITNESS: Again, I was not involved in  
25       naming the people who would serve on the committee, and

HANNAH KAUFMAN & ASSOCIATES, INC.

1       the deposition for you to reconsider your position after  
2       you've had some time to think about it, but I'll move on  
3       right now to my next question.

4           Q. Whether real ad hoc committee or not, can you  
5       think of any reviewing body -- peer reviewing body that  
6       did not include a member that had the same specialty as  
7       the person being reviewed?

8           MR. VANDALL: The question lacks foundation,  
9       and again, are we getting into questions about  
10      third-party peer review here while the plaintiff is in  
11      the room.

12          MR. SWEET: Q. You can answer the question.

13          THE WITNESS: It's unclear. Can you state it  
14      again, please.

15          MR. SWEET: Q. Sure. Can you think of any ad  
16      hoc committee that did not include a member on it who  
17      had the same specialty as the person being reviewed?

18          MR. VANDALL: The question lacks foundation.

19          THE WITNESS: This is the only ad hoc  
20      committee I've ever been involved in.

21          MR. SWEET: Q. So the answer technically is  
22      no; correct?

23          A. Correct.

24          Q. Can you think of any peer review committee  
25          that did not include a member that had the same

HANNAH KAUFMAN & ASSOCIATES, INC.

1 specialty as the person being reviewed?

2 MR. VANDALL: Same objections.

3 THE WITNESS: Not that I'm aware of.

4 MR. SWEET: Q. Were you concerned that  
5 Dr. Dat Ly was on the ad hoc committee since he had  
6 worked in the operating room with Dr. Ennix?

7 A. No.

8 Q. Did you know that fact?

9 MR. VANDALL: Vague as to time period.

10 THE WITNESS: I'm not certain that I knew that  
11 fact, no.

12 MR. SWEET: Q. Did Dr. Dat Ly ever tell you  
13 that he worked in the operating room with Dr. Ennix?

14 A. No.

15 Q. Were you concerned that you had been selected  
16 to be on the ad hoc committee given that you were a  
17 member of the surgery peer review committee who sat in  
18 the April 12, 2004 meeting?

19 A. No.

20 MR. VANDALL: It's about lunchtime. Is this a  
21 good time for a break?

22 MR. SWEET: Sure. It's 12:05. Let's come  
23 back at 1:00 o'clock.

24 MR. VANDALL: Great.

25 (Noon recess taken.)

HANNAH KAUFMAN & ASSOCIATES, INC.

1 well, but I believe his name is Dr. Kwan, and he was the  
2 head of the division of ear, nose and throat,  
3 otorhinolaryngology. Both of those surgeons were  
4 non-Caucasian physicians.

5 Q. Quan, Q-u-a-n?

6 A. I'm not certain of his name, the spelling, I  
7 believe it's K-w-a-n, but I may well be incorrect in  
8 that.

9 Q. Back to the April 12, 2004 surgery peer review  
10 committee meeting that we talked about this morning, was  
11 a vote taken of those present to decide what to do with  
12 the peer review of Dr. Ennix?

13 A. I don't recall the answer to that question.

14 Q. How does that typically work in that committee  
15 when a decision is made? Is it a vote? How does it  
16 work?

17 A. Typically, we would grade the -- when a case  
18 is being presented and then the reviewer of that case,  
19 the presenter, would then grade that case, and I believe  
20 in this sense it was a 1, 2 or a 3, and I believe that  
21 the committee members, my best recollection, would then  
22 vote on whether they -- what level that they thought  
23 that this was. So we would vote on situations like  
24 that.

25 Q. Did that happen in this particular case

HANNAH KAUFMAN & ASSOCIATES, INC.

1        regarding Dr. Ennix?

2            A. Whether we voted to grade the complication?

3            Q. Correct.

4            A. That's what we did in that committee, we  
5        discussed complications and the reviewer would give  
6        their opinion of the grade and we would vote whether we  
7        agree or whether we would change that to a 1 or 2 or 3  
8        and all cases that came up, we would discuss. That  
9        would be the case, the way it would work.

10          Q. And the process is the reviewer presents  
11        whatever information that they have and there's a vote  
12        as to how to grade it?

13          A. That's correct.

14          Q. To beat a dead horse, I guess, in this case  
15        Dr. Hon Lee at least from these minutes it appears did  
16        not actually present his findings personally, somebody  
17        else did perhaps; correct?

18          MR. VANDALL: Asked and answered.

19          MR. SWEET: Q. It has been, but is that  
20        right?

21          A. I'm sorry. Is what right again?

22          Q. The reviewer in this case, this case is  
23        different because the reviewer didn't present his  
24        findings; correct, somebody else presented them on his  
25        behalf?

HANNAH KAUFMAN & ASSOCIATES, INC.

1 discussions were pursued, so I can't answer that  
2 question.

3 Q. Did you have input regarding whom the ad hoc  
4 committee would or would not interview?

5 A. As I recall, when we first met, we  
6 collaboratively discussed between -- I believe it was  
7 the four of us -- three committee members and president  
8 of the medical staff, Dr. Isenberg, who we believe would  
9 be most appropriate to the interview in our evaluation  
10 of these cases.

11 Q. And how did you in the first instance come up  
12 with that list? What was it based on?

13 MR. VANDALL: Objection. Lacks foundation.

14 THE WITNESS: It was based on the persons who  
15 had interaction with Dr. Ennix and who we thought could  
16 give best evaluation opinions of these cases.

17 MR. SWEET: Q. Who were those first witnesses  
18 that you thought would be important to interview?

19 A. I don't recall them in exact order, but we  
20 thought that the cardiac surgeons, namely Dr. Russell  
21 Stanten and Dr. Janette Khan would be of importance. We  
22 thought that Dr. Steven Stanten, the chair of the  
23 department of surgery, would be important to interview,  
24 and also an anesthesiologist who worked with Dr. Ennix,  
25 we thought would be important to interview.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 issues regarding Dr. Ennix.

2 Q. Did Dr. Isenberg suggest these names?

3 A. He was involved in the process, yes.

4 Q. By the way, there's a lawyer present at this  
5 meeting; correct?

6 A. Yes.

7 Q. Whose idea was it to have a lawyer present at  
8 the ad hoc committee meetings?

9 MR. VANDALL: If you know.

10 THE WITNESS: I don't know the answer to that  
11 question.

12 MR. SWEET: I have to admonish Counsel that  
13 that is the exact prohibition in Judge Alsup's order,  
14 you cannot indicate to your witness that he should have  
15 some question about whether he knows an answer to  
16 something or not.

17 It's not the first time you've done it, and  
18 frankly, I've let you get away with it, but now I'm not  
19 going to. So there's your admonition, and I hope as one  
20 who's constantly citing to rules and regulations and  
21 statutes that you would be able to adhere to  
22 paragraph 24 of his order.

23 Q. I'm sorry.

24 A. My answer is the same, that I don't know, I  
25 have no knowledge why he attended. My impression was

HANNAH KAUFMAN & ASSOCIATES, INC.

1       that that was routine to have the medical staff legal  
2       counsel present during the ad hoc committee discussion.

3           Q. How were you elected chair of the committee?

4           A. I'm afraid by default. I went to answer a  
5       page, when I came back they had elected me. They asked,  
6       I went away to answer a page, and they said would you  
7       please be chair and I accepted.

8           Q. Who said that?

9           A. I don't recall. I think it was consensus of  
10      Dr. Isenberg, Dr. Dat Ly and Dr. Barry Horn.

11          Q. Did you want to be the chair?

12          A. I would say that I didn't have any prior  
13      desires to be the chair, no.

14          Q. Okay. There's an initial list of people to  
15      interview, and Dr. Ennix is not listed there, is he?

16          A. His name is not on this list.

17          Q. Why?

18          A. I don't know the answer to that question, but  
19      I would assume that this is a -- an initial list. It  
20      was expanded as we went on to include other people who  
21      would be appropriate, and I would image that it was  
22      always in our process to include Dr. Ennix in this  
23      process as being fair and balanced.

24          Q. But true, he's not listed on the initial list  
25      of possible interviewees; correct?

HANNAH KAUFMAN & ASSOCIATES, INC.

1       on August 30, 2004, this statistical information before  
2       you interviewed Dr. Ennix; correct?

3           A. I believe that's correct.

4           Q. And as this minute order suggests in  
5       paragraph 3, you are reviewing the Junoe report and  
6       discussing its contents before you interviewed  
7       Dr. Ennix; correct?

8           A. I believe that's correct.

9           Q. And in this minute order, and I think this is  
10       the second meeting of the ad hoc committee, you generate  
11       or the committee generates a list of people to  
12       interview, do you see that?

13           A. I do.

14           Q. In priority order, do you see that?

15           A. I do.

16           Q. Dr. Ennix doesn't appear anywhere on this  
17       list, does he?

18           A. His name is not on this list.

19           Q. And the last entry is the anesthesiologist  
20       from Alta Bates medical staff, so somebody thought it  
21       would be perhaps a good idea to interview an Alta Bates  
22       anesthesiologist; correct?

23           A. That's how it would appear.

24           Q. Did you ever?

25           A. I don't believe we did.

HANNAH KAUFMAN & ASSOCIATES, INC.

1       Q. Last three sentences, Dr. Lee was asked about  
2       STS risk adjusted data. Dr. Lee said that the  
3       cardiothoracic peer review group reviews data by  
4       surgeon, quote, I don't see any one physician falling  
5       out, unquote.

6                   What did that mean?

7       A. It would be my interpretation that he's saying  
8       that he does not see any one surgeon whose statistics  
9       are falling out.

10      Q. Was he telling you that the statistics that  
11     you were relying on did not indicate that Dr. Ennix,  
12     quote/unquote, fell out?

13                  MR. VANDALL: Calls for speculation.

14                  THE WITNESS: Well, I'm not a cardiac surgeon,  
15     that would be speculation on my part.

16                  MR. SWEET: Q. Back to the first page of this  
17     document, back to the paragraph in the middle there,  
18     starting Dr. Stanton then asked, four lines up from the  
19     bottom of that paragraph, starting Dr. Stanton, and I'll  
20     read it and I'm going to ask you some questions about  
21     it, Dr. Stanton stated that combining these concerns  
22     with other issues raised from the Alta Bates peer  
23     review, he felt these issues were not procedure related  
24     but physician related.

25                  What did that mean?

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. I don't see that written here.

2 Q. Well, did you?

3 A. And I don't recall if we specifically asked  
4 that question to Dr. Russell Stanton.

5 Q. So we could draw from this that the chair of  
6 the cardiothoracic surgery division was telling you that  
7 at least some of the statistics you were analyzing were  
8 not significant; right?

9 A. I believe he was saying that some of the  
10 statistics did not fall below standard of care, yes.

11 Q. Did you do anything to figure out which  
12 statistics he was talking about?

13 A. I believe we looked at other statistics that  
14 showed that there were patient care issues,  
15 morbidity/mortality issues, compared to his peers.

16 Q. This was the second time that Dr. Russell  
17 Stanton was in front of the ad hoc committee; is that  
18 right?

19 A. He interviewed twice with our committee.

20 Q. And in general, just a general flavor, was  
21 Dr. Russell Stanton's testimony at this meeting,  
22 October 27, 2004, favorable to Dr. Ennix or not  
23 favorable?

24 A. I'd have to look through the document again to  
25 characterize it as such.

HANNAH KAUFMAN & ASSOCIATES, INC.

1                   (Whereupon, Exhibit 1031 was marked for  
2 identification.)

3                   MR. SWEET: The next exhibit is a January 4,  
4 2005 letter from Dr. Paxton to Dr. Smithline. This is a  
5 five-page letter.

6                   Q. I'm going to ask that you not review it again,  
7 quite yet. Okay.

8                   My first question to you, Dr. Paxton -- I'm  
9 sorry. What number is this --

10                  THE REPORTER: 1031.

11                  MR. SWEET: Q. Who wrote this letter?

12                  A. I believe it was Dr. Isenberg and I.

13                  Q. Was it supposed to be a neutral letter? I  
14 don't think you need to read the letter to answer the  
15 question. Was it supposed to be a neutral letter, was  
16 that the intent?

17                  A. I don't recall that I would say that it's not  
18 neutral. I don't know what you're getting at.

19                  Q. Well, what was the purpose in paragraph 2 of  
20 telling the NMA at the bottom of that paragraph, that  
21 medical staff began to take an intensive interest in his  
22 practice. What was that meant to convey?

23                  A. That we had concerns about his cases and  
24 morbidity and mortality.

25                  Q. The next paragraph highlights, quote, specific

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. No.

2 Q. Do you know what the summary suspension was  
3 based on specifically?

4 A. I would have to review the records to be  
5 accurate, but I believe it was based on the  
6 falsification of a medical record.

7 Q. Were you told that the NMA report had any role  
8 in the summary suspension?

9 A. No.

10 Q. You were not told that?

11 A. Not to my recollection.

12 Q. With all of this happening between the  
13 October 28, 2004 meeting and your May 16, 2005 meeting,  
14 the summary suspension, the NMA report coming out, the  
15 pacemaker case, et cetera, looking back on it, do you  
16 think it would have been a more fair procedure had  
17 Dr. Ennix been talked to at that point?

18 A. I believe the way we handled this ad hoc  
19 committee with Dr. Ennix was performed quite fair and  
20 the manner in which we interviewed Dr. Ennix was  
21 performed in a very fair fashion as well.

22 Q. I'm still on the May 16, 2005 minutes, and now  
23 I'm on page 2, the first full paragraph reads the  
24 committee requested information regarding the basis for  
25 the summary suspension, Dr. Isenberg responded that he

## HANNAH KAUFMAN &amp; ASSOCIATES, INC.

1       consulted with the medical staff officers and then  
2       implemented the summary suspension based on the most  
3       recent incident in light of all the material currently  
4       available, paren, most notably the Mercer report, close  
5       paren, which indicates that continuing Dr. Ennix's  
6       privileges pending the completion of the investigation  
7       presents an imminent danger to the health or safety of  
8       an individual including current or future hospital  
9       patients. Do you see that?

10      A. I do.

11      Q. So Dr. Isenberg was telling the ad hoc  
12     committee that he relied on the Mercer report, most  
13     notably on the Mercer report to impose the summary  
14     suspension; right?

15      A. Well, I would interpret it that he implemented  
16     the summary suspension based on the most recent incident  
17     and in light of the available current material, the  
18     Mercer report, indicating that the doctor's privileges  
19     were being suspended due to the imminent danger to the  
20     health and safety of individuals.

21      Q. Dr. Paxton, if it was a falsification of a  
22     medical record, how would that imply imminent danger to  
23     the health and safety of a patient?

24      A. Well, I'm not certain that falsification of a  
25     record would necessarily put patients at risk, but it

HANNAH KAUFMAN & ASSOCIATES, INC.

1           A. I believe I reviewed the report, and then  
2 summarized in these paragraphs.

3           Q. So, for instance, it starts with ABS-10, under  
4 sub A and then it goes to ABS-007, that's how you  
5 presented it to your ad hoc committee?

6           A. It would appear so.

7           Q. At the end of that section, and I'm now at the  
8 bottom of D2004, which is page 3 of this minute, it  
9 concludes, with this passage, discussed role of  
10 cardiologist in these cases, should ad hoc committee  
11 interview the cardiologists involved in these cases. Do  
12 you see that?

13          A. Yes.

14          Q. Whose idea was it perhaps to interview  
15 cardiologists?

16          A. I don't recall specifically who made that  
17 comment.

18          Q. Did the ad hoc committee bother to interview  
19 cardiologists?

20           MR. VANDALL: Objection. Argumentative.

21           MR. SWEET: Perhaps.

22          Q. Did you interview cardiologists?

23          A. I believe the case was discussed with

24          Dr. Woodworth, with one of the cardiologists, yes.

25          Q. In what capacity?

HANNAH KAUFMAN & ASSOCIATES, INC.

1       A. To discuss these cases as he was involved in  
2       one of these cases. In the NMA report, and I can add I  
3       recall that they had said that perhaps that further  
4       cardiology intervention would have been appropriate as  
5       opposed to proceeding with urgent coronary bypass, and I  
6       believe that cardiologist was involved in this case.  
7       And I believe that that was discussed with him, although  
8       I don't recall the specifics of that.

9       Q. Let me refer you to the second to last page of  
10      this exhibit, D2008, which is entitled, Corrected  
11      Chronology of Ad Hoc Committee Meetings and  
12      Interviewees. Do you see that page?

13      A. I do.

14      Q. Is there a cardiologist listed anywhere on  
15      this list of the interviewees of the ad hoc committee?

16      A. There's not.

17      Q. So how was Dr. Woodworth involved in your ad  
18      hoc committee investigation?

19      A. I don't believe he was interviewed, but I  
20      think the case was discussed with him by the, I believe,  
21      the president of the medical staff.

22      Q. And how did this information get to you, to  
23      your committee, if you know?

24      A. I don't recall specifically.

25      Q. But certainly not in the form of testimony in

HANNAH KAUFMAN & ASSOCIATES, INC.

1           A. To the best of my recollection, I thought we  
2       had 19 meetings of our committee, but I could be  
3       incorrect on that.

4           Q. Right. I think you said you interviewed 19  
5       people.

6           A. No. Not interviewed.

7           Q. That was a misstatement.

8           Who wrote the investigative report and  
9       investigation issued by the ad hoc committee?

10          A. I believe it was a collaborative effort.

11          Q. Well, who typed it into the computer?

12          A. I believe it was typed in the computer by the  
13       medical staff.

14          Q. Who submitted -- who wrote the document that  
15       was submitted to the medical staff's secretary?

16          A. I believe it was the committee members and  
17       Dr. Isenberg.

18          Q. Are you indicating that different parts of the  
19       report were drafted by different committee members?

20          A. I wouldn't specifically say that, no.

21          Q. Was someone primarily responsible for drafting  
22       the report?

23          A. No. I think that we all had a role in  
24       drafting the report and submitting it together.

25          Q. At this late hour, I don't mean to argue with

HANNAH KAUFMAN & ASSOCIATES, INC.

1 A. I do.

2 Q. What does that mean, and on what do you base  
3 that?

4 A. We base that on the report that we had from  
5 our supervisors as well as the NMA report.

6 Q. Does, did not go well, mean that the patient  
7 care activities were outside the standard of care?

8 A. I don't know that I would characterize it on  
9 those terms.

10 Q. Were you involved, your ad hoc committee,  
11 involved in the proctoring that resulted with  
12 Dr. Ennix's privileges?

13 A. We reviewed the proctor reports.

14 Q. You mean, the ad hoc committee had an official  
15 role in proctoring, didn't it?

16 A. I wouldn't say we had an official role in  
17 proctoring. I believe we said that they would be  
18 proctored and that we would be involved in reviewing  
19 that proctored information.

20 MR. SWEET: I have another exhibit.

21 (Whereupon, Exhibit 1037 was marked for  
22 identification.)

23 MR. SWEET: Q. Dr. Paxton, this is a letter  
24 dated April 19, 2006 from the proctors; correct?

25 A. Yes.

HANNAH KAUFMAN & ASSOCIATES, INC.

1 Q. And it's sent to you; right?

2 A. Yes.

3 Q. And this is at a time period, April 19 was as  
4 the six-month proctoring restriction, the first set of  
5 six months was about to conclude; correct?

6 A. Yes.

7 Q. And this letter expresses to you the unanimous  
8 universally favorable reports from the proctors about  
9 Dr. Ennix's patient care activities; right?

10 A. I'll review it quickly.

11 Q. Is that accurate?

12 A. I'm sorry. Please restate.

13 Q. This letter is from all six proctors  
14 indicating that they have no problem with Dr. Ennix's  
15 patient care activities.

16 A. That's what it states.

17 Q. Did you receive this letter?

18 A. I believe the answer is yes.

19 Q. If I could have marked as next in order  
20 number 1038, please.

21 (Whereupon, Exhibit 1038 was marked for  
22 identification.)

23 MR. SWEET: Q. Dr. Paxton, this is the May 4,  
24 2006 report of the ad hoc investigating committee to the  
25 medical executive committee on the status of the

HANNAH KAUFMAN & ASSOCIATES, INC.

1 proctoring. Do you recognize this document and accept  
2 my representation as to what it is?

3 A. May I take a brief look?

4 Q. Sure.

5 A. Yes. Thank you.

6 Q. About two-thirds of the way down in this  
7 minute, it says, the AHC reached the conclusion that  
8 there were an inadequate number of cases to warrant a  
9 conclusion to lift the proctoring process. Do you see  
10 that?

11 A. I do.

12 Q. Is that what the AHC decided?

13 A. I believe it was the portion of the AHC that  
14 reviewed these that was the opinion.

15 Q. Which included you; correct?

16 A. It did.

17 Q. The point is that this is a report sent by you  
18 to the MEC at the six-month interval and whether or not  
19 to continue or discontinue the proctoring requirement,  
20 and you're recommending to continue it; correct?

21 A. That's what it states.

22 Q. Notwithstanding that you had received a letter  
23 from all of the proctors telling you that there was no  
24 need to continue the proctoring; correct?

25 A. I recall that Dr. Steven Stanton and I

HANNAH KAUFMAN & ASSOCIATES, INC.

1       reviewed these cases and read through the cases, the  
2       charts, the medical records, and it was our feeling that  
3       this was an inadequate number of cases to make a sound  
4       judgment to allow Dr. Ennix to lift the proctoring.

5           Q.    Okay. But my question was just a simple yes  
6       or no, that you and I guess Steve Stanton together  
7       decided that even though the proctors themselves said  
8       it's okay to stop the proctoring requirement, you and  
9       Steve Stanton decided to continue to recommend  
10      continuing the proctoring requirement; correct?

11          A.    We felt that there were inadequate number of  
12      cases to warrant a conclusion to lift the proctoring  
13      process.

14          Q.    I know your reason, but I just want to know so  
15      I have a clean record that you recommended to continue  
16      the proctoring requirement --

17          A.    We did.

18          Q.    -- and the reason is because you felt there  
19      were an inadequate number of cases to warrant the  
20      conclusion?

21          A.    Correct.

22          Q.    Why? I mean, what do you base that on?

23          A.    We base this on our opinion that there were an  
24      inadequate number of cases to judge the -- judge this  
25      and we felt that it would be most prudent in regard to

STATE OF CALIFORNIA

I do hereby certify that the witness in the foregoing deposition was by me duly sworn to testify the truth, the whole truth, and nothing but the truth in the within-entitled cause; that said deposition was taken at the time and place therein stated; that the testimony of the said witness was reported by me, a Certified Shorthand Reporter and a disinterested person, and was under my supervision thereafter transcribed into typewriting; that thereafter, the witness was given an opportunity to read and correct the deposition transcript, and to subscribe the same; that if unsigned by the witness, the signature has been waived in accordance with stipulation between counsel for the respective parties.

And I further certify that I am not of counsel or attorney for either or any of the parties to said deposition, nor in any way interested in the outcome of the cause named in said caption.

IN WITNESS WHEREOF, I have hereunto set my hand the 27th,  
day of December, 2007.



Certified Shorthand Reporter

CSR No. 12 978